Fused tricyclic heterocyclic compounds as hiv integrase inhibitors 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2017113288 A1 2017-07-06 [WO2017113288] / 2017-07-06
申请号/申请日
2015WO-CN100106 / 2015-12-31
发明人
YU TAO;WADDELL SHERMAN T;GRAHAM THOMAS H;MCCAULEY JOHN A;STAMFORD ANDREW W;CAI JIAQIANG;QI ZHIQI;
申请人
MERCK SHARP & DOHME;
主分类号
IPC分类号
A61K-031/5025A61P-031/18C07D-471/16C07D-487/16
摘要
(WO2017113288) The present invention relates to Fused Tricyclic Heterocyclic Compounds of Formula (I) :and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein.  The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocyclic Compound, and methods of using the Fused Tricyclic Heterocyclic Compounds for treating or preventing HIV infection in a subject.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2015WO-CN100106 2015-12-31
主权利要求

        
法律状态
(WO2017113288) LEGAL DETAILS FOR WO2017113288  Actual or expected expiration date=2019-06-30    Legal state=ALIVE    Status=PENDING     Event publication date=2015-12-31  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOCN2015100106  Application date=2015-12-31  Standardized application number=2015WO-CN100106     Event publication date=2017-07-06  Event code=WO/A1  Event type=Examination events  Published application with search report  Publication country=WO  Publication number=WO2017113288  Publication stage Code=A1  Publication date=2017-07-06  Standardized publication number=WO2017113288  LEGAL DETAILS FOR DESIGNATED STATE EP  Actual or expected expiration date=2035-12-31    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=EP Corresponding appl: EP15911914    Event publication date=2017-09-06  Event code=WO/121  Event type=Designated states  EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc:  Designated or member state=EP
专利类型码
A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部